Skip to main content
Erschienen in: Clinical and Translational Oncology 12/2014

Open Access 01.12.2014 | Editorial

SEOM guidelines 2014: improving quality to increase its usefulness

verfasst von: P. Garrido, C. A. Rodríguez

Erschienen in: Clinical and Translational Oncology | Ausgabe 12/2014

download
DOWNLOAD
print
DRUCKEN
insite
SUCHEN
Since 2010, when the Spanish Society for Medical Oncology (SEOM) started publishing clinical practice guidelines for the management of solid tumours and supportive care, the challenges have evolved from educational purposes to policy purposes. Due to our increasingly complex system, patient care requires cohesive documents on which to base daily decisions [13] and SEOM is really committed to working on balancing both sustainability and equity in the access to new treatment options.
The aim of the guidelines was to combine updates of common tumours as well as to introduce new issues. This is one the reasons that explains their success as a consolidated project [4]. In the current edition, an independent external committee has been added to ensure the utmost rigour based on the level of evidence and grades of recommendations while maintaining their high practical value. There is no doubt that this decision will increase their value.
The nine guidelines to be published include highly relevant topics such as prevention and screening, hydroelectrolitic disorders, prostate cancer, management of thromboembolic events, renal cancer, gastroenteropancreatic neuroendocrine tumours, thyroid cancer, ovarian tumours and cancer of unknown origin.
While earlier diagnosis and advances in treatment have considerably improved survival in recent years, further progress is needed. In the light of the current status of knowledge, primary and secondary prevention of the most prevalent neoplasms (breast, cervix, prostate, colon and lung) are reviewed by SEOM experts. One of the greatest challenges is the fact that current therapies for advanced diseases are not curative, necessitating treatment over a number of years and placing a significant health care burden on society. To reduce this burden, care delivery must be more efficient and cost-effective. In particular, developments of adequate screening programs are needed, along with preventative strategies [5].
This is the first time that guidelines on hydroelectrolytic disorders have been included. We are aware of the importance acquired by some recent advances in this field and the need for comprehensive training in symptoms common to different tumours [6]. Similarly, a review of the management of thromboembolic events has also been considered. Venous thromboembolic events in oncological patients are very common and have specific challenges. These guidelines summarise the most recent recommendations about prophylaxis and treatment of these events, as well as help to address some doubts about specific clinical problems [7].
The options for patients with prostate cancer have recently increased with the addition of several new treatments that need to be analysed from a medical oncology perspective [8]. Similarly, the approaches to the available options for renal cancers have been updated [9].
Gastroenteropancreatic Neuroendocrine Neoplasms are a challenging family of tumours of growing incidence and varied clinical management. Significant advances in the diagnosis and the understanding of the molecular biology of these tumours have been achieved. Diagnostic workup, histological and staging classifications and the different available therapeutic approaches are briefly discussed in the manuscript from a practical point of view [10].
A further example of recent advances in the diagnosis, molecular biology and systemic therapeutics is thyroid cancer. This is the reason why new recommendations have been considered necessary [11]. Treatment options for the management of ovarian carcinoma have been also updated, including the most recent findings regarding their biology and new targeted therapies [12].
Last but not least, we still have the challenge of managing patients with “cancer of unknown origin”. This is a constantly changing area where a delicate balance is continuously needed. SEOM guidelines are intended to help oncologists in making their decisions [13].

Acknowledgments

Members of the independent review committee (in alphabetical order): Aparicio J, Arranz JA, Camps C, Cruz JJ, Cubedo R, Esteban E, Pachón V, Poveda A and Salazar R. Members of the executive board of the SEOM: Garrido P, Martín M, Aparicio J, Barón FJ, García-Campelo R, García-Carbonero R, Lianes P, Llombart A, Muñoz M, Rivera F, Rodríguez CA and Virizuela JA.

Conflict of interest

None.
Open AccessThis article is distributed under the terms of the Creative Commons Attribution License which permits any use, distribution, and reproduction in any medium, provided the original author(s) and the source are credited.
download
DOWNLOAD
print
DRUCKEN

Unsere Produktempfehlungen

e.Med Interdisziplinär

Kombi-Abonnement

Für Ihren Erfolg in Klinik und Praxis - Die beste Hilfe in Ihrem Arbeitsalltag

Mit e.Med Interdisziplinär erhalten Sie Zugang zu allen CME-Fortbildungen und Fachzeitschriften auf SpringerMedizin.de.

e.Med Innere Medizin

Kombi-Abonnement

Mit e.Med Innere Medizin erhalten Sie Zugang zu CME-Fortbildungen des Fachgebietes Innere Medizin, den Premium-Inhalten der internistischen Fachzeitschriften, inklusive einer gedruckten internistischen Zeitschrift Ihrer Wahl.

Literatur
1.
2.
Zurück zum Zitat Isla D, González A, Alba E. The relevance of Spanish society for medical oncology (SEOM) clinical oncology guidelines. Clin Transl Oncol. 2010;12(11):707–8.CrossRef Isla D, González A, Alba E. The relevance of Spanish society for medical oncology (SEOM) clinical oncology guidelines. Clin Transl Oncol. 2010;12(11):707–8.CrossRef
3.
Zurück zum Zitat Rodriguez CA, Cruz-Hernández JJ. SEOM guidelines 2013: a response to the needs of Spanish oncologists. Clin Transl Oncol. 2013;15(12):975–6.PubMedCrossRef Rodriguez CA, Cruz-Hernández JJ. SEOM guidelines 2013: a response to the needs of Spanish oncologists. Clin Transl Oncol. 2013;15(12):975–6.PubMedCrossRef
4.
Zurück zum Zitat Cruz-Hernandez JJ, Rodríguez CA. SEOM clinical guidelines: a consolidated project. Clin Transl Oncol. 2012;14(7):489–90.PubMedCrossRef Cruz-Hernandez JJ, Rodríguez CA. SEOM clinical guidelines: a consolidated project. Clin Transl Oncol. 2012;14(7):489–90.PubMedCrossRef
5.
Zurück zum Zitat Segura PP, Fombella JPB, Lorenzo BP, Martín MR, Lopez PG. SEOM guide to primary and secondary prevention of cancer: 2014. Clin Transl Oncol. 2014. doi:10.1007/s12094-014-1215-5. Segura PP, Fombella JPB, Lorenzo BP, Martín MR, Lopez PG. SEOM guide to primary and secondary prevention of cancer: 2014. Clin Transl Oncol. 2014. doi:10.​1007/​s12094-014-1215-5.
6.
7.
Zurück zum Zitat Muñoz Martín AJ, Font Puig C, Navarro Martín LM, Borrega García P, Martín Jiménez M. Clinical guide SEOM on venous thromboembolism in cancer patients. Clin Transl Oncol. 2014. doi:10.1007/s12094-014-1238-y. Muñoz Martín AJ, Font Puig C, Navarro Martín LM, Borrega García P, Martín Jiménez M. Clinical guide SEOM on venous thromboembolism in cancer patients. Clin Transl Oncol. 2014. doi:10.​1007/​s12094-014-1238-y.
8.
Zurück zum Zitat Cassinello J, Climent MA, González del Alba A, Mellado B, Virizuela JA. SEOM Clinical guidelines for the treatment of metastatic prostate cancer. Clin Transl Oncol. 2014. doi:10.1007/s12094-014-1225-3. Cassinello J, Climent MA, González del Alba A, Mellado B, Virizuela JA. SEOM Clinical guidelines for the treatment of metastatic prostate cancer. Clin Transl Oncol. 2014. doi:10.​1007/​s12094-014-1225-3.
9.
Zurück zum Zitat Bellmunt J, Puente J, Garcia de Muro J, Lainez N, Rodríguez C, Duran I. SEOM clinical guidelines for the treatment of renal cell carcinoma. Clin Transl Oncol. 2014. doi:10.1007/s12094-014-1219-1. Bellmunt J, Puente J, Garcia de Muro J, Lainez N, Rodríguez C, Duran I. SEOM clinical guidelines for the treatment of renal cell carcinoma. Clin Transl Oncol. 2014. doi:10.​1007/​s12094-014-1219-1.
10.
Zurück zum Zitat Garcia-Carbonero R, JImenez-Fonseca P, Teulé A, Barriuso J, Sevilla I. SEOM clinical guidelines for the diagnosis and treatment of gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs) 2014. Clin Transl Oncol. 2014. doi:10.1007/s12094-014-1214-6. Garcia-Carbonero R, JImenez-Fonseca P, Teulé A, Barriuso J, Sevilla I. SEOM clinical guidelines for the diagnosis and treatment of gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs) 2014. Clin Transl Oncol. 2014. doi:10.​1007/​s12094-014-1214-6.
13.
Zurück zum Zitat Martín RC, Palomo AG, de la Cruz Merino L, García PB, Duarte FJB. Clinical guideline SEOM: cancer of unknown primary site. Clin Transl Oncol. 2014. doi:10.1007/s12094-014-1244-0. Martín RC, Palomo AG, de la Cruz Merino L, García PB, Duarte FJB. Clinical guideline SEOM: cancer of unknown primary site. Clin Transl Oncol. 2014. doi:10.​1007/​s12094-014-1244-0.
Metadaten
Titel
SEOM guidelines 2014: improving quality to increase its usefulness
verfasst von
P. Garrido
C. A. Rodríguez
Publikationsdatum
01.12.2014
Verlag
Springer Milan
Erschienen in
Clinical and Translational Oncology / Ausgabe 12/2014
Print ISSN: 1699-048X
Elektronische ISSN: 1699-3055
DOI
https://doi.org/10.1007/s12094-014-1246-y

Weitere Artikel der Ausgabe 12/2014

Clinical and Translational Oncology 12/2014 Zur Ausgabe

Clinical Guides in Oncology

Thyroid cancer: SEOM clinical guidelines

Clinical Guides in Oncology

SEOM guideline in ovarian cancer 2014

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.